The Government Pharmaceutical Organization (GPO) in Pathum Thani has received certification from the World Health Organization (WHO) under its Prequalification Programme (WHO PQ) for producing Efavirenz, an essential antiretroviral medication.

GPO director Mingkwan Suphanpong announced the certification as a first for both Thailand and the ASEAN region. This milestone ensures that Efavirenz tablets manufactured at the facility remain on the WHO Prequalified List. The WHO initially approved the drug in 2018 after the GPO applied in 2016.

Efavirenz is a standard treatment for HIV-positive individuals and is often combined with tenofovir and emtricitabine. It is also used in post-exposure prophylaxis regimens to reduce HIV infection risks.

The certification follows a detailed inspection in August 2024, covering manufacturing processes, support systems, and quality management. Valid for three years, this recognition underscores GPO’s dedication to producing high-quality, cost-effective generic drugs, which contribute significantly to Thailand’s healthcare system.

Ms. Mingkwan emphasized the importance of continued research and development in generic medications to ensure timely access to affordable alternatives when drug patents expire. This achievement aligns with WHO’s policy on HIV suppression, which states that individuals with undetectable viral loads pose no risk of transmission.

Jarunee Siriphan, an advocate for HIV rights, praised the “Undetectable Equals Untransmittable” (U=U) campaign, highlighting its role in empowering people living with HIV (PLHIV). She urged the Public Health Ministry to certify and promote this approach to combat workplace discrimination against PLHIV.

However, Ms. Jarunee stressed that employers must not misuse the policy by requiring proof of viral suppression, as such demands infringe on personal rights. She called on the state to set an example in eliminating discrimination against PLHIV in all sectors.